Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 17/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 17/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 17/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 17/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atipamezole SCHEMBL29357620 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1BTAAR1 | |
| Atipamezole SCHEMBL30249868 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1B | |
| Atipamezole SCHEMBL203964 | 0.98 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18826054 | 0.88 | ADRA2A (0.78) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9527262 | 0.85 | ADRA2A (0.74) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL31683943 | 0.84 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1BTAAR1 | |
| SCHEMBL18826064 | 0.84 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1BTAAR1 | |
| SCHEMBL29467258 | 0.84 | ADRA2A (0.74) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18826068 | 0.84 | ADRA2A (0.74) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18826059 | 0.83 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3392 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076950-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | NOEMA PHARMA AG (CH) | 2026-03-19 | — | — | US | claimed |
| US-20250345324-A1 | COMBINATION FORMULATIONS OF NALOXONE AND ATIPAMEZOLE | Joshi, Hemant Narahar (US) | 2025-11-13 | — | — | US | claimed |
| US-12414937-B2 | Local and regional anesthesia and analgesia | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-09-16 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| US-20250177376-A1 | ALPHA 2 ADRENERGIC RECEPTOR BLOCKADE FOR THE TREATMENT OF C. DIFFICILE COLITIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-06-05 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12280057-B2 | Vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing | SOUTH DAKOTA BOARD OF REGENTS (US) | 2025-04-22 | — | — | US | claimed |
| WO-2025034510-A1 | ADRENERGIC ANTAGONISTS FOR USE IN A METHOD FOR TREATING CEREBRAL EDEMA OR A BRAIN INJURY | UNIVERSITY OF ROCHESTER (US) | 2025-02-13 | — | — | WO | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| US-5492907-A | ADMINISTERING AN ALPHA2-ADRENERGIC RECEPTOR ANTAGONIST AND A D2 DOPAMINE RECEPTOR ANTAGONIST; TREATS SCHIZOPHRENIA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1996-02-20 | — | — | US | claimed |
| US-5434177-A | Imidazoles for the treatment of age-related cognitive disorders and alzheimer | ORION-YHTYMA OY (FI) | 1995-07-18 | — | — | US | claimed |
| EP-0589957-A1 | USE OF ATIPAMEZOLE FOR THE TREATMENT OF MALE SEXUAL IMPOTENCE. | ORION YHTYMAE OY (FI) | 1994-04-06 | — | — | EP | claimed |
| EP-0536179-A1 | BIOCERAMIC SYSTEM FOR DELIVERY OF BIOACTIVE COMPOUNDS | ORION-YHTYMÀ OY (FI) | 1993-04-14 | — | — | EP | claimed |
| EP-0532553-A1 | COMPOUNDS FOR THE TREATMENT OF AGE-RELATED MEMORY IMPAIRMENT AND OTHER COGNITIVE DISORDERS. | ORION YHTYMAE OY (FI) | 1993-03-24 | — | — | EP | claimed |
| WO-1992022296-A1 | USE OF ATIPAMEZOLE FOR THE TREATMENT OF MALE SEXUAL IMPOTENCE | Orion-Yhtymä Oy (FI) | 1992-12-23 | — | — | WO | claimed |
| US-5109007-A | Administering atipamezole and idazoxan | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-04-28 | — | — | US | claimed |
| WO-1992000109-A1 | BIOCERAMIC SYSTEM FOR DELIVERY OF BIOACTIVE COMPOUNDS | Orion-Yhtymä Oy (FI) | 1992-01-09 | — | — | WO | claimed |
| WO-1991018886-A1 | COMPOUNDS FOR THE TREATMENT OF AGE-RELATED MEMORY IMPAIRMENT AND OTHER COGNITIVE DISORDERS | Orion-Yhtymä Oy (FI) | 1991-12-12 | — | — | WO | claimed |
| US-4968692-A | Attenuation of ethyl alcohol intoxication with alpha-2 adrenoceptor antagonists | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-11-06 | — | — | US | claimed |